Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma

Figure 1 Radiological response categories by mRECIST and Irecist. The figure shows the number (%) of patients per radiological response category. ORR: Overall response rate; DCR: Disease control rate.

Figure 2 Biological (alpha-fetoprotein) response categories. The figure shows the number (%) of patients per biological response category. AFP: Alpha-fetoprotein; ORR: Overall response rate; DCR: Disease control rate.

Figure 3 Overall and progression-free survival. The graph shows the Kaplan-Meier survival curves for overall and progression-free survival. Below the graph the number of patients still alive at that time is depicted. OS: Overall survival; PFS: Progression-free survival.

Figure 4 Survival per radiological and biological response. A and B: The graph shows the Kaplan-Meier survival curves for each category of radiological (A) and biological (B) response. Below the graph the number of patients still alive at that time is depicted. AFP: Alpha-fetoprotein; AFP decrease: AFP decrease without normalization.

Figure 5 Evolution of the World Health Organization performance status after 2 mo and 4 mo of treatment, compared to baseline. A and B: The figure shows the proportion of patients with an improved, a stable, and a worse World Health Organization performance status after 2 mo (A) and after 4 mo (B) compared to baseline. WHO PS: World Health Organisation performance status.